bioAffinity Technologies, Inc. (BIAF)
NASDAQ: BIAF · Real-Time Price · USD
3.170
-0.400 (-11.20%)
At close: Oct 22, 2026, 4:00 PM EDT
3.160
-0.010 (-0.32%)
After-hours: Oct 22, 2026, 5:10 PM EDT
bioAffinity Technologies Revenue
bioAffinity Technologies had revenue of $1.51M in the quarter ending June 30, 2026, with 18.99% growth. This brings the company's total for the last twelve months to $5.90M, down -23.17% year-over-year. In the year 2025, bioAffinity Technologies had annual revenue of $6.16M, down -34.18%. That makes bioAffinity Technologies the 39,399th largest company in the world by revenue and 5,215th in the United States.
Revenue (ttm)
$5.90M
Revenue Growth
-23.17%
P/S Ratio
0.75
Revenue / Employee
$103,526
Employees
57
Market Cap
4.07M
Revenue by Segment
- Laboratory Services 6.16M 100.0%
- Diagnostic R&D 577.00 0.0%
Fiscal year ended Dec 31, 2025 See the full bioAffinity Technologies breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 6.16M | -3.20M | -34.18% |
| Dec 31, 2024 | 9.36M | 6.83M | 269.68% |
| Dec 31, 2023 | 2.53M | 2.53M | 52,627.44% |
| Dec 31, 2022 | 4.80K | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| MDxHealth | 114.02M |
| Biodesix | 102.94M |
| Burning Rock Biotech | 73.70M |
| Exagen | 71.12M |
| XWELL | 28.28M |
| Precipio | 27.20M |
| Insight Molecular Diagnostics | 1.67M |
| Quantum Cyber | 537.08K |
BIAF News
- 7 days ago - BioAffinity to present new perspectives on CyPath Lung at CHEST 2026 - TheFly
- 7 days ago - bioAffinity Technologies to Present New Perspectives on CyPath® Lung's Use for Cancer Risk Assessment at CHEST 2026 - Business Wire
- 9 days ago - BioAffinity Technologies to present new data at CHEST 2026 - TheFly
- 9 days ago - bioAffinity Technologies to Present Positive Research Data in Development of Its New Test Measuring Asthma and COPD-Related Lung Inflammation and Drug-Related Receptors at CHEST 2026 - Business Wire
- 9 days ago - bioAffinity Technologies Proxy statement: Proxy filing - Filings
- 13 days ago - WallachBeth Capital Announces Closing of bioAffinity Technologies $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules - PRNewsWire
- 13 days ago - BioAffinity Technologies announces closing of $4M registered direct financing - TheFly
- 13 days ago - bioAffinity Technologies, Inc. Announces Closing of $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules - Business Wire